Full Text
PCN93 COST-MINIMIZATION ANALYSIS OF XELOX (CAPECITABINE OXALIPLATIN) AS ADJUVANT TREATMENT IN STAGE III COLON CANCER UNDER THE BRAZILIAN PRIVATE PAYER PERSPECTIVE

Abstract

Authors

G Prolla LG Borges E Santos

Back to Volume 13, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×